23andMe launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options. “Health Action Plan is a powerful tool for customers, combining genetic and non-genetic data, along with lab testing to tailor health recommendations,” said Robin Smith, Ph.D., Director of Product Management at 23andMe. “This feature provides customers with a prioritized to-do list of recommendations based on their DNA that’s updated as new reports are released or additional scientific discoveries are made.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ME:
- 23andMe enters collaboration extension with data licensing agreement with GSK
- 23andMe to Report FY2024 Second Quarter Financial Results
- 23andMe (NASDAQ:ME) Turns Attention to Genetic Disorders
- 23andMe discloses user accounts data breach
- 23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting